An Accelerated Progression Relapse Test (APRT) is provided for use in the prognosis of a diseased state in a patient. The APRT provides a determination of when a patient in a particular diseased state is likely to benefit from further disease treatment, or does not have a high probability of benefit with additional treatment. In particular applications, the APRT may be used to determine the prognosis of an estrogen receptor positive (ER+) breast cancer patient. Four genetic probes are disclosed for this test, and target MK167, CDC6 and SPAG5 gene products. The ER+ breast cancer patient/patient population is stratified into two groups, with the low gene expression group identifying the patient/patient group that is less likely to benefit from additional treatment measures, and a high gene expression group identifying the patient/patient group as more likely to benefit from additional treatment measures.